

State of Oklahoma SoonerCare

Zydelig[®] (Idelalisib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Pharmacy Billing (NDC:) Start Date (or date of next dose):	
Dose: Regimen:		
Billing Provider Information		
Pharmacy NPI:	Pharmacy Na	me:
Pharmacy Phone:	Pharmacy Fax	c
Prescriber Information		
Prescriber Phone:	_ Prescriber Fax:	Specialty:
Criteria Cri		
 Will idelalisib be used as second-line or subsequent therapy? Yes No Will idelalisib be used for relapsed or refractory disease? Yes No Please indicate the diagnosis and information: Gastric or Nongastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma, Nodal or Splenic Marginal Zone Lymphoma (MZL) A. Refractory to alkylator therapy? Yes No B. Refractory to rituximab therapy? Yes No Chronic Lymphocytic Leukemia (CLL) A. Will idelalisib be used as a single agent? Yes No B. Will idelalisib be used in combination with rituximab? Yes No If diagnosis is not listed above, please indicate diagnosis: Additional Information: 		
For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on idelalisib? Yes No 3. Has the member experienced any adverse drug reactions related to idelalisib therapy? Yes No If yes, please specify adverse reactions: Additional Information:		
I certify that the indicated treatment is med	dically necessary and all informat	Date:tion is true and correct to the best of my knowledge. sary. Failure to complete this form in full will result in

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 103 4/28/2023